RT Journal Article
SR Electronic
T1 VEXAS syndrome is characterized by blood and tissues inflammasome pathway activation and monocyte dysregulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.12.22281005
DO 10.1101/2022.10.12.22281005
A1 Kosmider, Olivier
A1 Possémé, Céline
A1 Templé, Marie
A1 Corneau, Aurélien
A1 Carbone, Francesco
A1 Duroyon, Eugénie
A1 Chirayath, Twinu-Wilson
A1 Luka, Marine
A1 Gobeaux, Camille
A1 Lazaro, Estibaliz
A1 Outh, Roderau
A1 Le Guenno, Guillaume
A1 Lifermann, François
A1 Berleur, Marie
A1 Friedrich, Chloé
A1 Lenormand, Cédric
A1 Weitten, Thierry
A1 Guillotin, Vivien
A1 Burroni, Barbara
A1 Sohier, Pierre
A1 Boussier, Jay
A1 Willems, Lise
A1 Aractingi, Selim
A1 Dionet, Léa
A1 Tharaux, Pierre-Louis
A1 Vergier, Béatrice
A1 Raynaud, Pierre
A1 Ea, Hang-Korng
A1 Ménager, Mickael
A1 Duffy, Darragh
A1 Terrier, Benjamin
YR 2022
UL http://medrxiv.org/content/early/2022/10/17/2022.10.12.22281005.abstract
AB Acquired mutations in the UBA1 gene, occurring in myeloid cells and resulting in expression of a catalytically impaired isoform of the enzyme E1, were recently identified in patients with severe adult-onset auto-inflammatory syndrome called VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic). The precise physiological and clinical impact of these mutations remains poorly defined.Here, we studied a unique prospective cohort of individuals with severe autoinflammatory disease with (VEXAS) or without (VEXAS-like) UBA1 somatic mutations and compared with low-risk myelodysplastic syndromes (MDS) and aged gender-matched healthy controls. We performed an integrated immune analysis including multiparameter phenotyping of peripheral blood leukocytes, cytokines profiling, bulk and single-cell gene expression analyses and skin tissue imaging mass cytometry.Focusing on myeloid cells, we show that monocytes from UBA1-mutated individuals were quantitatively and qualitatively impaired and displayed features of exhaustion with aberrant expression of chemokine receptors. Within affected tissues, pathological skin biopsies from VEXAS patients showed an abundant enrichment of CD16+ CD163+ monocytes adjacent to blood vessels and M1 macrophages, possibly promoting local inflammation in part through STAT3 activation. In peripheral blood from VEXAS patients, we identified a significant increase in circulating levels of many proinflammatory cytokines, including IL-1β and IL-18 which reflect inflammasome activation and markers of myeloid cells dysregulation. Gene expression analysis of whole blood confirmed the role of circulating cells in the IL-1β and IL-18 dysregulation in VEXAS patients and revealed a significant enrichment of TNF-α and NFκB signaling pathways that could mediate cell death and inflammation. Single-cell analysis confirmed the inflammatory state of monocytes from VEXAS patients and allowed us to identify specific molecular pathways that could explain monocytopenia, especially the activation of PANoptosis and a deficiency in the TYROBP/DAP12 axis and β-catenin signaling pathway. Together, these findings on monocytes from patients with UBA1 mutations provide important insights into the molecular mechanisms involving the mature myeloid commitment in VEXAS syndrome and suggest that the control of the undescribed inflammasome activation and PANoptosis could be novel therapeutic targets in this condition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Fonds IMMUNOV, for Innovation in Immunopathology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This non-interventional study was conducted between January, 2021 and May, 2021, in the setting of the local RADIPEM biological samples collection derived from samples collected in routine care. Biological collection and informed consent were approved by the Direction de la Recherche Clinique et Innovation (DRCI) and the French Ministry of Research (2019-3677). A written informed consent was collected for all participants. None of the study participants received compensation. This study was conducted in compliance with the Good Clinical Practice protocol and the principles of the Declaration of Helsinki, and received approval from the Cochin Hospital Institutional Review Board (number AAA-2021-08040).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data supporting the findings of this study are available within the article or from the corresponding authors upon reasonable request without any restrictions.